Abbott Laboratories (ABT)vsZimmer Biomet Holdings Inc (ZBH)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
ZBH
Zimmer Biomet Holdings Inc
$87.64
+1.53%
HEALTHCARE · Cap: $17.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 439% more annual revenue ($44.33B vs $8.23B). ABT leads profitability with a 14.7% profit margin vs 8.6%. ZBH appears more attractively valued with a PEG of 0.60. ZBH earns a higher WallStSmart Score of 59/100 (C).
ABT
Buy51
out of 100
Grade: C-
ZBH
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Margin of Safety
-296.1%
Fair Value
$24.14
Current Price
$87.64
$63.50 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
ROE of 5.6% — below average capital efficiency
Weak financial health signals
Earnings declined 40.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : ZBH
The strongest argument for ZBH centers on Price/Book, PEG Ratio. Revenue growth of 10.9% demonstrates continued momentum. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : ZBH
The primary concerns for ZBH are Return on Equity, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ABT carries more volatility with a beta of 0.74 — expect wider price swings.
ZBH is growing revenue faster at 10.9% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ZBH scores higher overall (59/100 vs 51/100) and 10.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Zimmer Biomet Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?